DE60231986D1 - Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose - Google Patents

Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Info

Publication number
DE60231986D1
DE60231986D1 DE60231986T DE60231986T DE60231986D1 DE 60231986 D1 DE60231986 D1 DE 60231986D1 DE 60231986 T DE60231986 T DE 60231986T DE 60231986 T DE60231986 T DE 60231986T DE 60231986 D1 DE60231986 D1 DE 60231986D1
Authority
DE
Germany
Prior art keywords
bases
nebularine
hypoxanthine
combinations
uracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231986T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Zdenek Richard Holan
Reader Stephanie Dr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DE60231986D1 publication Critical patent/DE60231986D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
DE60231986T 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose Expired - Lifetime DE60231986D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31329001P 2001-08-17 2001-08-17
PCT/IB2002/003323 WO2003016528A2 (en) 2001-08-17 2002-08-19 Oligonucleotide compositions and their use to induce apoptosis

Publications (1)

Publication Number Publication Date
DE60231986D1 true DE60231986D1 (de) 2009-05-28

Family

ID=23215136

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60231986T Expired - Lifetime DE60231986D1 (de) 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
DE60211206T Expired - Lifetime DE60211206T2 (de) 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose induzierenden phosphodiesteroligonukleotiden

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60211206T Expired - Lifetime DE60211206T2 (de) 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose induzierenden phosphodiesteroligonukleotiden

Country Status (14)

Country Link
US (5) US7199228B2 (de)
EP (2) EP1417307B1 (de)
JP (2) JP4504015B2 (de)
KR (2) KR101017483B1 (de)
AT (2) ATE325341T1 (de)
AU (2) AU2002330663B2 (de)
CA (2) CA2457783A1 (de)
DE (2) DE60231986D1 (de)
DK (1) DK1417307T3 (de)
ES (1) ES2325247T3 (de)
HK (1) HK1069205A1 (de)
IL (4) IL160408A0 (de)
MX (2) MXPA04001315A (de)
WO (2) WO2003016567A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
EP2363133A1 (de) * 2000-03-31 2011-09-07 Trustees of Boston University Zusammensetzung enhalted DNA-Fragmente und ihre medizinischen und kosmetischen Verwendungen
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
EP1417307B1 (de) * 2001-08-17 2009-04-15 Bioniche Life Sciences Inc. Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
WO2004014312A2 (en) * 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
AU2010317683A1 (en) * 2009-11-10 2012-05-24 Bioniche Life Sciences Inc. Non-DNA base-containing polynucleotide compositions and their use for the modulation of immune responses
CN106709925A (zh) * 2016-12-30 2017-05-24 上海联影医疗科技有限公司 医学图像中椎块的定位方法及其装置
CN107704697B (zh) * 2017-10-18 2019-08-20 西南交通大学 一种型材三维拉弯成形性预测评价优化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106727A (en) * 1989-04-27 1992-04-21 Life Technologies, Inc. Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
WO1993018187A1 (en) * 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
DE69609161T2 (de) * 1995-01-19 2001-03-22 Gen Probe Inc Amplifikationsoligonukleotide und sonden für borrelia, die mit lyme kranheit assoziiert sind
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
AU777910B2 (en) * 1999-04-08 2004-11-04 Gen-Probe Incorporated Amplification and sequencing primer pairs and use thereof
JP4772245B2 (ja) * 1999-12-13 2011-09-14 バイオニケ ライフ サイエンシーズ インコーポレイテッド 治療上有用な合成オリゴヌクレオチド
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
EP1417307B1 (de) 2001-08-17 2009-04-15 Bioniche Life Sciences Inc. Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Also Published As

Publication number Publication date
JP4504015B2 (ja) 2010-07-14
KR20040032925A (ko) 2004-04-17
WO2003016567A2 (en) 2003-02-27
US20030144233A1 (en) 2003-07-31
US7200531B2 (en) 2007-04-03
IL160407A0 (en) 2004-07-25
IL160408A0 (en) 2004-07-25
JP2005521119A (ja) 2005-07-14
WO2003016528A3 (en) 2003-10-09
US20080077372A1 (en) 2008-03-27
US20110160291A1 (en) 2011-06-30
IL160408A (en) 2010-05-31
DE60211206T2 (de) 2006-10-26
US7893242B2 (en) 2011-02-22
US20030113763A1 (en) 2003-06-19
WO2003016528A2 (en) 2003-02-27
IL160407A (en) 2010-02-17
WO2003016567A3 (en) 2004-06-03
KR100943567B1 (ko) 2010-02-22
EP1417307B1 (de) 2009-04-15
ATE325341T1 (de) 2006-06-15
CA2457783A1 (en) 2003-02-27
KR20040030138A (ko) 2004-04-08
DK1417307T3 (da) 2009-07-13
ATE428781T1 (de) 2009-05-15
EP1448986A2 (de) 2004-08-25
MXPA04001315A (es) 2004-05-20
HK1069205A1 (en) 2005-05-13
US20080081793A1 (en) 2008-04-03
MXPA04001480A (es) 2004-05-20
AU2002326067B2 (en) 2007-05-31
EP1448986B1 (de) 2006-05-03
KR101017483B1 (ko) 2011-02-25
AU2002330663B2 (en) 2007-09-20
EP1417307A2 (de) 2004-05-12
JP4469603B2 (ja) 2010-05-26
US7199228B2 (en) 2007-04-03
CA2457789A1 (en) 2003-02-27
DE60211206D1 (de) 2006-06-08
US8350016B2 (en) 2013-01-08
ES2325247T3 (es) 2009-08-31
JP2005509411A (ja) 2005-04-14

Similar Documents

Publication Publication Date Title
HK1069205A1 (en) Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
Taylor DNA, sunlight and skin cancer
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
BR0311343A (pt) Derivados de piridazina
IL173888A0 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
DE60234278D1 (de) Mitotische kinesin-hemmer
AR019011A1 (es) Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
ECSP055561A (es) Procesos para la preparación de pirimidinas sustituidas y derivados de pirimidina como inhibidores de las proteínas quinasas
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
BR0315689A (pt) Alvo para terapia de dano cognitivo
DK0988301T3 (da) Imidazolylcykliske acetaler
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
DK1045690T3 (da) Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
BRPI0415355A (pt) triarilimidazóis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition